Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry PerspectiveTonika Bohnert, Susanna Tse, Heidi J. Einolf et al.|Drug Metabolism and Disposition|2016Cited by 110
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive ControlNiresh Hariparsad, Donald Tweedie, Diane Ramsden et al.|Drug Metabolism and Disposition|2017Cited by 46
Considerations from the IQ induction working group in response to drug–drug interaction guidances from regulatory agenciesNiresh Hariparsad, Donald Tweedie, Heidi J. Einolf et al.|Drug Metabolism and Pharmacokinetics|2018Cited by 0